Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 17Cyclophosphamide 16Ifosfamide 11fludarabine 9Radiotherapy 8tazemetostat 5pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Quality of Life 2Nivolumab 2Molecular Diagnostic Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × drozitumab × Clear all
NCT00543712 2022-12-13

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Genentech, Inc.

Phase 2 Terminated
15 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡